New PET imaging model for quantifying cardiac amyloidosis can enable more accurate diagnosis and monitoring

Researchers have identified the optimal tracer kinetic model to quantify 18F-flutemetamol myocardial uptake in patients with transthyretin (ATTR) cardiac amyloidosis. Presented at the 2023 Society of Nuclear Medicine and Molecular Imaging Annual Meeting, this method allows physicians to obtain a fully quantitative measurement of cardiac amyloidosis burden and response to treatment for the first time.